New GMP (Good Manufacturing Practice) facility to meet increasing demand for lipid nanoparticle (LNP) development and clinical drug product manufacturing.
Until further notice, Rettig is taking over the duties of Christian Kullmann, who is recovering in the coming weeks from a recent serious, unplanned surgery.
Danish pharma Novo Nordisk is expanding its R&D capabilities in Boston, Massachusetts, US, which will lead to the closure of a facility in Indianapolis and a restructuring of its Seattle operations.
Cambrex is advancing its $150 million investment to expand API manufacturing in Iowa and enhance R&D and manufacturing capabilities in Milan, strengthening its services in the US and Europe.
